Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 239

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 6
Chunk 239
---
 matter who       
    are present and voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or
------------------------------------------------------------------------------------------------------------------------

•   the shares voted by shareholders who have no personal interest in the matter who are present and vote against
                    the transaction represent no more than 2% of the voting rights in the company.               
-----------------------------------------------------------------------------------------------------------------
 
The terms of service and employment of a controlling shareholder approved by the compensation committee and board of directors shall be in accordance with the compensation policy of the company. Nonetheless, the compensation committee and the board of directors may, in special circumstances, approve a compensation arrangement of a controlling shareholder that does not comply with the company’s compensation policy, provided that (i) the compensation committee and, thereafter, the board of directors approve such terms, based on, among other things, the considerations and mandatory requirements with respect to a compensation policy set forth in the Companies Law and (ii) the shareholders have approved the terms by means of the Special Majority for Compensation.
 
To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval, in the same manner described above, is required once every three years, unless, with respect to transactions not involving the receipt of services or compensation can be approved for a longer term, the audit committee determines that the duration of the transaction for such longer term is reasonable given the related circumstances.
 
Pursuant to regulations promulgated under the Israeli Companies Law, certain transactions, including with respect to compensation, with a controlling shareholder or his or her relative, or with directors or other office holders, that would otherwise require approval of a company’s shareholders may be exempt from shareholder approval under certain conditions.
 

Approval of Significant Private Placements
 
Under the Companies Law, a significant private placement of securities requires approval by the board of directors and the shareholders by a simple majority. A private placement is considered a significant private placement if it will cause a person to become a controlling shareholder (within the meaning of the Companies Law) or if all of the following conditions are met: (i) the securities issued amount to 20% or more of the company’s outstanding voting rights before the issuance; (ii) some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and (iii) the transaction will increase the relative holdings of a shareholder who holds 5% or more of the company’s outstanding share capital or voting rights or that will cause any person to become, as a result of